Following the announcement of the final outcome of Diamyd Medical AB's (publ) ("Diamyd Medical" or the "Company") rights issue carried out in April 2025, it has come to the Company’s attention that, due to administrative reasons, one subscription application was not included in the final outcome. As a result, an adjustment has been necessary. After this adjustment, the number of subscribed A-units in the rights issue amounts to 514,624 and the number of subscribed B-units amounts to 27,686,603. Consequently, this means that the number of B-units issued within the framework of the additional unit issue included in the rights issue amounts to 2,409,103. Through the rights issue, the additional unit issue, and the directed issue carried out on May 5, 2025, the Company will thus receive approximately SEK 267 million before issue costs, adjusted from the previously communicated amount of approximately SEK 266 million.

Following the registration of the rights issue, the additional unit issue, and the directed issue, the Company's share capital will amount to SEK 13,945,395.1198, comprised of 137,499,723 shares, of which 3,503,120 are A-shares and 133,996,603 are B-shares.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd^{® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. An early read-out of the Phase 3 trial is expected in March 2026. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group – both in a largescale meta-analysis as well as in the Company’s prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.}

Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:

Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on May 15, 2025, 15.10 CET.